Legal & General Group Plc Buys New Stake in Edwards Lifesciences Corporation $EW

Legal & General Group Plc purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,301,222 shares of the medical research company’s stock, valued at approximately $389,089,000. Legal & General Group Plc owned approximately 0.75% of Edwards Lifesciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company purchased a new position in Edwards Lifesciences in the second quarter valued at $131,472,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Edwards Lifesciences in the second quarter worth about $554,000. Van Hulzen Asset Management LLC purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $3,211,000. Peak Asset Management LLC purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $559,000. Finally, L2 Asset Management LLC acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $315,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 2,425 shares of company stock valued at $219,199. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Stock Up 0.5%

EW stock opened at $90.92 on Wednesday. The stock has a market capitalization of $52.35 billion, a P/E ratio of 52.25, a P/E/G ratio of 2.37 and a beta of 0.85. The firm has a 50-day simple moving average of $89.35 and a 200-day simple moving average of $84.82. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Citigroup increased their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Mizuho raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, UBS Group assumed coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price for the company. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.